VYNE Therapeutics Inc.
VYNE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $19 | $22 | $28 | $20 |
| Short-Term Investments | $13 | $18 | $22 | $42 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $3 | $5 | $5 | $3 |
| Total Curr. Assets | $36 | $44 | $55 | $64 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $1 | $2 |
| Total NC Assets | $0 | $0 | $2 | $2 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $36 | $45 | $56 | $67 |
| Liabilities | – | – | – | – |
| Payables | $1 | $1 | $4 | $3 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $3 | $4 | $9 | $12 |
| Total Curr. Liab. | $4 | $6 | $12 | $15 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $4 | $6 | $12 | $15 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$753 | -$746 | -$740 | -$731 |
| AOCI | $0 | -$0 | $0 | $0 |
| Other Equity | $785 | $784 | $784 | $783 |
| Total Equity | $32 | $39 | $44 | $52 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $36 | $45 | $56 | $67 |
| Net Debt | -$19 | -$22 | -$28 | -$20 |